Features of the transforming growth factor β1 parameters in the blood serum among children with varying severity of bronchial asthma and varying volume of basic therapy

Objective: the study to relationship between the concentration of transforming growth factor β1 (TGF-β1) in the blood serum of patients with bronchial asthma (BA), depending on the severity of the disease and the volume of basic therapy. Materials and methods. A comprehensive examination of 159 children suffering from atopic asthma was conducted, of which 79 (49.7 %) patients had mild asthma, 33 (20.75 %) had moderate asthma, and 47 (29.55 %) patients had severe asthma. The control group included 30 children of health groups I and IIa. All children included in the study had their serum concentrations of TGF-β1 determined by ELISA using Human TGF-β1 Platinum ELISA kits manufactured by Bender MedSystems GmbH, Austria (Bender MedSystems GmbH, Campus Vienna Biocenter 2, 1030 Vienna, Austria). Statistical processing of the obtained data was carried out using the Statistics 12.0 software package. Results. The results of the conducted studies have shown that TGF-β1 plays a significant role in the pathogenesis of asthma. And the study of changes in the concentration of this cytokine in patients depending on the volume of basic therapy makes us think about the development of new targeted therapeutic drugs to optimize pharmacotherapeutic approaches to the treatment of this disease. Conclusion. The results of the conducted studies showed that TGF-β1 not only plays a significant role in the pathogenesis of BA, but also affects the severity of clinical manifestations of the disease. It was found that in patients with severe asthma, TGF-β1 values were lower than in mild asthma (p = 0.009). And the study of changes in the concentration of this cytokine in patients showed the presence of increased values in patients receiving monotherapy with ICS. The results obtained are quite ambiguous and make one think about continuing research in this scientific direction.